NCT06978647View on ClinicalTrials.gov

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 19, 2025

Primary Completion Date

May 19, 2026

Study Completion Date

May 19, 2027

Conditions
Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Inflammatory MyopathyAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisAntiphospholipid Syndrome (APS)Rheumatoid Arthritis (RA)IgG4-Related DiseasesSjogren's Syndrome
Interventions
DRUG

YTS109 cell

Subjects will receive YTS109 cell (1.5 E6 STAR +T cells/kg) once in this study.

Trial Locations (1)

100853

RECRUITING

The First Medical Center of Chinese PLA General Hospital, Beijing

All Listed Sponsors
collaborator

The First Medical Center of Chinese PLA General Hospital

OTHER

lead

China Immunotech (Beijing) Biotechnology Co., Ltd.

INDUSTRY